Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of TA-650 in Patients With Refractory Kawasaki Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed with Kawasaki disease (incipient cases only) with 5 or more of the 6 major symptoms of Kawasaki disease.~* Patients refractory to initial IVIG therapy (a single administration at 2 g per kg body weight).~* Patients with a fever of 37.5ºC or higher axillary temperature at the time of enrollment.~* Patients to whom the study drug can be administered by day 8 of disease.~Exclusion Criteria:~* Patients who have received vaccination with Bacille Calmette-Guérin (BCG) vaccine within 6 months before the enrollment.~* Patients with a complication, or a history within 6 months before the enrollment of, serious infections requiring hospitalization.~* Patients with a complication, or a history within 6 months before the enrollment of, opportunistic infections.~* Patients complicated with active tuberculosis, active hepatitis B or C, or patients confirmed to be hepatitis B virus carriers or a history of hepatitis B.~* Patients confirmed to have HIV infection, or patients with a family history of HIV infection.~* Patients who have a history of receiving treatment with infliximab or other biological products.~* Patients who had participated in another clinical study and had received a study drug within 12 weeks before giving consent.

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 10 Years
- Healthy Volunteers: f

Study Arms:
- TA-650 (Type: EXPERIMENTAL): None
- VGIH (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).